This cash-burning biotech sits below the minimum quality threshold with high short interest and a predominantly negative earnings track record, rendering the technically constructive price action and analyst optimism insufficient grounds for a standard position.
Thesis pillars
- Below Minimum Quality Threshold→Stable
- Elevated Bearish Market Positioning→Stable
- Earnings Miss Dominant Pattern→Stable
- +1 more pillar — see the Why tab for full reasoning
ArriVent BioPharma, Inc. (AVBP) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $34.67: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 18%; Below-average business quality.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase... Read more
Sell if holding. Engine safety override at $34.67: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 18%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.9/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 42d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About ArriVent BioPharma, Inc.
About ArriVent BioPharma, Inc.
ArriVent BioPharma's lead asset, firmonertinib, is in two pivotal Phase 3 trials for non-small cell lung cancer: FURVENT, which enrolled 398 patients with EGFR exon 20 insertion mutations and expects topline data in mid-2026, and ALPACCA, targeting PACC mutations, which dosed its first patient in December 2025. ArriVent licensed firmonertinib from Shanghai Allist Pharmaceuticals in 2021 for all territories outside greater China, and the FDA has granted the drug Breakthrough Therapy and Orphan Drug designations.
ArriVent has never generated product revenue and its commercial revenue, if any, will initially come from firmonertinib sales, not expected for years even if approved; the company posted a $166.3 million net loss in 2025 against a $404.6 million accumulated deficit. Under its license agreements, ArriVent owes Allist up to $765.0 million and Lepu Biopharma up to $1.17 billion in development, regulatory, and sales milestone payments, plus tiered net-sales royalties to both partners, and up to $98.0 million in milestones to Aarvik Therapeutics under a separate antibody-drug-conjugate collaboration. Firmonertinib, ARR-217, and preclinical candidate ARR-002 are all manufactured by Chinese third parties for clinical development, and ArriVent expects to rely on the same manufacturers for future commercial supply. Beyond its lead asset, the company is building an ADC pipeline through Aarvik's conjugation platform and a 2024 collaboration with Jiangsu Alphamab Biopharmaceuticals.
Show full overview
ArriVent's entire clinical and prospective commercial supply chain runs through Chinese contract manufacturers: the 10-K states that the company relies on Chinese third parties for the manufacture of firmonertinib, ARR-217, and ARR-002, and expects to continue relying on third parties for the foreseeable future, with no in-house manufacturing capacity disclosed. That concentration compounds a separate structural dependency: ArriVent's risk factor summary states that the company currently depends significantly on the success of firmonertinib alone, with ARR-217 still in Phase 1 and no other clinical-stage asset positioned to offset a setback. A trial delay, an FDA objection to non-U.S. patient data (several firmonertinib and ARR-217 trials run in China), or a Chinese manufacturing disruption would each hit the same single value driver.
See also: Healthcare · Biotechnology
From ArriVent BioPharma, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-06Recent Developments — ArriVent BioPharma, Inc.
Latest news
- NEWS Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45 — benzinga May 29, 2026 positive
- NEWS Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $43 — benzinga May 13, 2026 neutral
- NEWS ArriVent Biopharma Launches $250M At-The-Market Common Stock Offering Through Jefferies — benzinga May 11, 2026 negative
- NEWS ArriVent BioPharma Q1 EPS $(0.96) Misses $(0.86) Estimate — benzinga May 11, 2026 negative
- NEWS ArriVent BioPharma Receives IND Application Clearance From FDA For ARR-002 Treatment For Ovarian And Endometrial Cancers — benzinga May 7, 2026 positive
Generated 2026-07-06T04:40:26Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $34.67: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 18%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $32.24. Score 4.9/10, moderate confidence.
Take-profit target: $37.96 (+9.5% upside). Prior stop was $32.24. Stop-loss: $32.24.
Quality below floor (1.6 < 4.0).
ArriVent BioPharma, Inc. trades at a P/E of N/A (forward -9.9). TrendMatrix value score: 6.0/10. Verdict: Sell.
19 analysts cover AVBP with a consensus score of 4.3/5. Average price target: $44.
What does ArriVent BioPharma, Inc. do?ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and...
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.